Humacyte, Trestle Biotherapeutics announce research collaboration

Trestle Biotherapeutics announced a research collaboration with Humacyte (HUMA). The collaboration will explore technology synergies for bioengineering vascularized organs for transplantation. The aim of the recently announced research collaboration and material transfer agreement is for the two companies to explore potential avenues of technology integration. The collaboration offers both groups the opportunity to expand their own R&D programs while exploring the interaction of Trestle Bio’s biofabricated human kidney tissues with Humacyte’s acelluar tissue engineered vessel-tyod, with a goal of generating a human bioengineered kidney with vascular perfusion.